Undervalued Drug Manufacturer Stocks on NYS August 2024

August 24, 2024

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
PRGO Perrigo 29.25 52.44 79.30 1482641 4010 3.75 0.0
ELAN Elanco Animal Health 14.57 19.87 36.39 5268418 7200 0.00 0.0
OGN Organon 22.36 26.56 18.78 2038453 5782 5.01 5.8
ZTS Zoetis 182.17 209.92 15.23 1993057 83070 0.92 35.5
JNJ Johnson & Johnson 164.13 188.35 14.75 7146421 397523 2.93 24.8
GSK GSK 42.63 44.49 4.37 3603856 87860 3.59 14.4
BHC Bausch Health Companies 5.87 5.95 1.30 2443709 2173 0.00 0.0
RDY Dr Reddy's Laboratories 82.16 82.47 0.37 216861 13703 0.58 20.7
NVS Novartis 118.56 118.89 0.28 1069129 242574 3.19 24.2
All data provided as at market close August 22, 2024.

Company Details

Perrigo

PRGO:NYS

Close Price

29.25

Our Valuation

52.44

% Difference

79.30

Market Cap ($M)

4010

P/E Ratio

0.0

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS.

Access the stockcalc valuation


Elanco Animal Health

ELAN:NYS

Close Price

14.57

Our Valuation

19.87

% Difference

36.39

Market Cap ($M)

7200

P/E Ratio

0.0

Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.

Access the stockcalc valuation


Organon

OGN:NYS

Close Price

22.36

Our Valuation

26.56

% Difference

18.78

Market Cap ($M)

5782

P/E Ratio

5.8

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan.

Access the stockcalc valuation


Zoetis

ZTS:NYS

Close Price

182.17

Our Valuation

209.92

% Difference

15.23

Market Cap ($M)

83070

P/E Ratio

35.5

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Johnson & Johnson

JNJ:NYS

Close Price

164.13

Our Valuation

188.35

% Difference

14.75

Market Cap ($M)

397523

P/E Ratio

24.8

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Access the stockcalc valuation


GSK

GSK:NYS

Close Price

42.63

Our Valuation

44.49

% Difference

4.37

Market Cap ($M)

87860

P/E Ratio

14.4

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Access the stockcalc valuation


Bausch Health Companies

BHC:NYS

Close Price

5.87

Our Valuation

5.95

% Difference

1.30

Market Cap ($M)

2173

P/E Ratio

0.0

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Access the stockcalc valuation


Dr Reddy's Laboratories

RDY:NYS

Close Price

82.16

Our Valuation

82.47

% Difference

0.37

Market Cap ($M)

13703

P/E Ratio

20.7

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr.

Access the stockcalc valuation


Novartis

NVS:NYS

Close Price

118.56

Our Valuation

118.89

% Difference

0.28

Market Cap ($M)

242574

P/E Ratio

24.2

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Perrigo and Elanco Animal Health are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-august-2024
Perrigo $PRGO and Elanco Animal Health $ELAN are the most undervalued Drug Manufacturers stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-august-2024
Perrigo and Elanco Animal Health are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-august-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.